Back to Journals » Biologics: Targets and Therapy » Volume 20
Biologics: Targets and Therapy
- View all (605)
- Volume 20, 2026 (18)
- Volume 19, 2025 (56)
- Volume 18, 2024 (35)
- Volume 17, 2023 (17)
- Volume 16, 2022 (18)
- Volume 15, 2021 (40)
- Volume 14, 2020 (13)
- Volume 13, 2019 (17)
- Volume 12, 2018 (19)
- Volume 11, 2017 (14)
- Volume 10, 2016 (18)
- Volume 9, 2015 (17)
- Volume 8, 2014 (27)
- Volume 7, 2013 (28)
- Volume 6, 2012 (46)
- Volume 5, 2011 (9)
- Volume 4, 2010 (31)
- Volume 3, 2009 (45)
- Volume 2, 2008 (89)
- Volume 1, 2007 (48)
Archive: Volume 20, 2026
Vunakizumab for IL-17A–Mediated Diseases: A Review in Psoriasis and Spondyloarthritis
Yan H, Chen Y, Song Y, Yan M, Yan K
Biologics: Targets and Therapy 2026, 20:500475
Published Date: 8 June 2026
Immunological Biomarkers in Glioblastoma: Targeting T and NK Cells for Enhanced Diagnosis and Prognosis
Akbari AM, Bourbour S, Seyedmehdi MS, Shiari S, Rustamzadeh A, Seif F, Farivar S
Biologics: Targets and Therapy 2026, 20:603545
Published Date: 29 May 2026
MicroRNA-661 Suppresses Proliferation and Migration of Pulmonary Artery Smooth Muscle Cells and Endothelial Cells by Targeting CCND2
Jiang L, Yang A, Liu J, Zhou J
Biologics: Targets and Therapy 2026, 20:592879
Published Date: 28 May 2026
Vunakizumab and Acitretin for Elderly Refractory Generalized Pustular Psoriasis: A Case Report and Comprehensive Literature Review
Deng S, Jiang Y, Li W, Shu Z, Chen T, Liang J, Zhang X
Biologics: Targets and Therapy 2026, 20:592069
Published Date: 22 May 2026
Rapid Resolution of Psoriasis Following Low-Dose Interleukin-2 Monotherapy: A Case Report
Ma D, Li Z
Biologics: Targets and Therapy 2026, 20:595201
Published Date: 20 May 2026
Long-Term TIE2 Inhibition in a TEK-Mutated Venous Malformation: A 3-Year Clinical Experience
Triana P, Marín E, Mendieta C, Fernández L, Rodriguez-Laguna L, Lopez-Gutierrez JC
Biologics: Targets and Therapy 2026, 20:606831
Published Date: 19 May 2026
Optimization of Recombinant Human Interferon-Gamma Expression and Purification in E. coli, and Developing an Immunization Protocol for the Production of Optimal Humoral Response
Uwituze V, Mugasa CM, Namayanja M, Nalumenya DP, Ndayisenga J, Ssekatawa K, Kato CD
Biologics: Targets and Therapy 2026, 20:584180
Published Date: 16 April 2026
Enhancement of Gastric Mucosal Defense by Phytomedicine in the Context of H. pylori–Associated Ulcer Disease
Paulraj RS, Perumal P, Ramachandran A, Sathiyaseelan A
Biologics: Targets and Therapy 2026, 20:597797
Published Date: 14 April 2026
Rheumatoid Factor Beyond Rheumatoid Arthritis: A Potential Marker of Cardiometabolic and Hepatic Risk
Egba SI, Orhonigbe IO, Achi NK, Ikechukwu GC, Chukwu CN, Omeoga CH
Biologics: Targets and Therapy 2026, 20:603345
Published Date: 13 April 2026
Safety and Efficacy of Mesenchymal Stem Cell Therapy in Multiple System Atrophy: Systematic Review
Elimam N, Albarari SS, Shaalan Y, Elsheikh SM, Alzamari AA, Elmekkawi N, Mogahed R, Alghuweiri RH
Biologics: Targets and Therapy 2026, 20:593367
Published Date: 31 March 2026
Anifrolumab in Refractory Oral Manifestations in Systemic Lupus Erythematosus: A Case Report and Literature Review
Garmish O, Smiyan S, Komorovsky R, Bilozetskyi I
Biologics: Targets and Therapy 2026, 20:588071
Published Date: 16 March 2026
Late-Onset Ocular Myasthenia Gravis–Like Symptoms During Erenumab Therapy for Chronic Migraine: A Case Report
Qaqish A, Al Anber A, Abdelhafez G
Biologics: Targets and Therapy 2026, 20:579731
Published Date: 4 March 2026
First-Line Serplulimab versus Other Anti-PD-1/PD-L1 Antibodies Plus Chemotherapy for Esophageal Squamous Cell Carcinoma: A Systematic Review with Benefit-Risk Assessment via Matching-Adjusted Indirect Comparison
Zhu Y, Qi X, Ni S, Qiu W, Chen M
Biologics: Targets and Therapy 2026, 20:602654
Published Date: 28 February 2026
Network Pharmacology-Based Exploration: Non-Targeted Metabolites of Lactobacillus-Fermented Chaenomeles speciosa (Sweet) Nakai, Smilax glabra Roxb. and Pueraria montana var. Lobata in Uric Acid Metabolism Intervention
Tan W, Li Z
Biologics: Targets and Therapy 2026, 20:578004
Published Date: 24 February 2026
Net Present Value Impact of FDA’s Phase 3 Waivers on Monoclonal Antibody Biosimilar Development
Ranbhor R, Kulkarni P
Biologics: Targets and Therapy 2026, 20:581013
Published Date: 10 February 2026
Successful and Risk-Minimizing Treatment of Ulcerative Colitis by Positive Switch from JAK Inhibitors to Ustekinumab
Otake H, Matsumoto S, Mashima H
Biologics: Targets and Therapy 2026, 20:561965
Published Date: 20 January 2026
Teclistamab for Relapsed or Refractory Multiple Myeloma: A Review of Efficacy, Safety, Resistance Mechanisms and Future Directions
Piron B, Moreau P, Touzeau C
Biologics: Targets and Therapy 2026, 20:539066
Published Date: 13 January 2026
Research on the Role of Autophagy in Vascular Endothelial Cells in the Healing of Chronic Refractory Wounds
Riling L, Kunyue F, Liyan G, Yaya W, Baoling N, Jiehui L
Biologics: Targets and Therapy 2026, 20:573844
Published Date: 13 January 2026